BioStock: 2023 springboard for Spago’s radionuclide cancer therapy

In 2023, Swedish biotech Spago Nanomedical kicked off its journey in the clinic with radionuclide cancer therapy Tumorad. Ending the year with the first patient dosed in the phase I trial and a SEK 30.6 million capital raise, Spago has strong momentum going into 2024. BioStock spoke with Spago’s CEO Mats Hansen to hear about the progress made in 2023 and what he is most looking forward to this year.

Read the interview with Mats Hansen at biostock.se:

2023 springboard for Spago’s radionuclide cancer therapy - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/